Castle Ebit from 2010 to 2024

CSTL Stock  USD 30.57  1.06  3.59%   
Castle Biosciences EBIT yearly trend continues to be quite stable with very little volatility. EBIT may rise above about -54.5 M this year. From the period between 2010 and 2024, Castle Biosciences, EBIT regression line of its data series had standard deviation of  22,475,196 and standard deviation of  22,475,196. View All Fundamentals
 
EBIT  
First Reported
2018-03-31
Previous Quarter
8.2 M
Current Value
8.5 M
Quarterly Volatility
10.8 M
 
Covid
Check Castle Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Castle Biosciences' main balance sheet or income statement drivers, such as Tax Provision of 125 K, Net Interest Income of 10.3 M or Interest Income of 10.3 M, as well as many indicators such as Price To Sales Ratio of 2.5, Dividend Yield of 0.0 or PTB Ratio of 1.55. Castle financial statements analysis is a perfect complement when working with Castle Biosciences Valuation or Volatility modules.
  
Check out the analysis of Castle Biosciences Correlation against competitors.
For more information on how to buy Castle Stock please use our How to buy in Castle Stock guide.

Latest Castle Biosciences' Ebit Growth Pattern

Below is the plot of the Ebit of Castle Biosciences over the last few years. It is Castle Biosciences' EBIT historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Castle Biosciences' overall financial position and show how it may be relating to other accounts over time.
Ebit10 Years Trend
Slightly volatile
   Ebit   
       Timeline  

Castle Ebit Regression Statistics

Arithmetic Mean(20,890,965)
Geometric Mean14,313,779
Coefficient Of Variation(107.58)
Mean Deviation18,290,059
Median(10,710,204)
Standard Deviation22,475,196
Sample Variance505.1T
Range73.6M
R-Value(0.67)
Mean Square Error297.4T
R-Squared0.45
Significance0.01
Slope(3,383,907)
Total Sum of Squares7071.9T

Castle Ebit History

2024-54.5 M
2023-57.4 M
2022-68.9 M
2021-40 M
2020-7.6 M
20194.7 M
2018-4.1 M

Other Fundumenentals of Castle Biosciences

About Castle Biosciences Financial Statements

Castle Biosciences investors utilize fundamental indicators, such as Ebit, to predict how Castle Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
EBIT-57.4 M-54.5 M
EBITDA-45 M-42.8 M
Ebt Per Ebit 0.84  1.28 
Ebit Per Revenue(0.31)(0.32)

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Castle Biosciences is a strong investment it is important to analyze Castle Biosciences' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Castle Biosciences' future performance. For an informed investment choice regarding Castle Stock, refer to the following important reports:
Check out the analysis of Castle Biosciences Correlation against competitors.
For more information on how to buy Castle Stock please use our How to buy in Castle Stock guide.
You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Castle Biosciences. If investors know Castle will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Castle Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.93)
Earnings Share
0.21
Revenue Per Share
11.34
Quarterly Revenue Growth
0.395
Return On Assets
(0)
The market value of Castle Biosciences is measured differently than its book value, which is the value of Castle that is recorded on the company's balance sheet. Investors also form their own opinion of Castle Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Castle Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Castle Biosciences' market value can be influenced by many factors that don't directly affect Castle Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Castle Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Castle Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Castle Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.